In general, biosimilars are generic products of biopharmaceuticals. Different from generics, they are “similar” and therefore require approval procedures similar to new branded drugs.   Although there are about 25 approved biosimilars in Europe, they did not receive the same treatment in the United States. Despite 11 drugs are approved in the United States, only about 3 kinds can be utilized in patients for branded pharmaceutical companies are using commercial…